Figure 1. CP-25 treatment attenuates clinical signs in rats with AA.

(A) Chemical structures of CP-25 and Pae. CP-25 (C₂₉H₃₂O₁₃S, MW: 620); Pae (C₂₃H₂₈O₁₁, MW: 480.45). (B) Photographs of representative paws from each AA group. (C,D) Arthritic scores of immunized Lewis rats treated either with drugs or vehicle beginning at the onset of disease (day 17) and continuing for 13 days. CP-25, TGP and Pae were administered intragastrically each day, and MTX was given intragastrically once every 3 days. Swelling of the non-injected hind paw and the polyarthritis index were assessed at 3-day intervals.^#P < 0.05, ^##P < 0.01 versus vehicle, ^ΔP < 0.05 versus TGP and Pae (n = 8–10 per group). (E) The body weights of the Lewis rats were measured and calculated. ^#P < 0.05, ^##P < 0.01 versus vehicle (n = 8–10 per group).